Jointly provided by Impact Education, LLC and Postgraduate Institute for Medicine.
|
This activity is supported by independent educational grants from Bristol-Myers Squibb and Merck & Co., Inc.
|
Wednesday, March 27, 2019
6:00 PM - 8:00 PM
San Diego Convention Center
Room: 15AB
San Diego, CA
Please note: No additional fee is required to attend this CME/CPE activity; however, registration to the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019 is required.
|
|
Click here to download the slides from this symposium.
If you attended this symposium and need to complete an evaluation or claim credit, click here and register or login. Type in 14030 at the top of the page under "Find Post-Test/Evaluation by Course". Complete the online evaluation and obtain your certificate to download and/or print for your files.
|
|
Hot Topics
|
- Key outcomes measures in immuno-oncology
- MOAs of novel immuno-oncology agents
- Payer cost-sharing and benefit design approaches to innovative immuno-oncology agents
- Initiatives for the funding and management of PD-1/PD-L1 inhibitors and CAR-T therapies
|
Expert Faculty Presenters
|
|
|
|
|
Jeffrey Dunn, PharmD, MBA
Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management
|
|
John Fox, MD, MHA
Vice President, Associate Chief Medical Officer
Medical Affairs
Priority Health
|
|
Joan H. Schiller, MD
Chief, Division of Hematology and Oncology
Deputy Director of Harold C. Simmons Comprehensive Cancer Center
Andrea L. Simmons Distinguished Chair in Cancer Research
University of Texas Southwestern Medical Center
|
|
|
|
Who Should Attend?
|
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP 2019 Managed Care and Specialty Pharmacy Annual Meeting.
|
|
Statement of Need/Program Overview
|
The recent emergence of immuno-oncology agents has demonstrated promise for further revolutionizing cancer care. True to their name, these drugs extend the concept of targeted cancer therapies by leveraging the ability of the body’s immune system to effectively respond to oncogenic processes. The advent and rapid escalation of targeted cancer therapies has led to the emergence of sophisticated immuno-oncology agents. However, the historically high cost of these agents has compelled payers to initiate strategies to control utilization and manage costs. This symposium will provide health care decision makers and managed care professionals with the required education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Characterize the role of the immune system in immunosurveillance and elimination of malignant cell lines with respect to cancer immunoediting
- Describe the mechanisms of action of novel immuno-oncology agents such as PD-1 and PD-L1 inhibitors and CAR-T therapies
- Describe key outcomes measures in immuno-oncology and characterize the importance of cumulative assessment of outcomes
- Apply comprehensive analyses of clinical trial data pertaining to recently approved and investigational PD-1/PD-L1 inhibitors and CAR-T therapies
- Characterize the incongruent application of traditional payer cost-sharing and benefit design approaches to the management of innovative immuno-oncology agents
- Evaluate current and proposed payer initiatives for the funding and management of PD-1/PD-L1 inhibitors and CAR-T therapies
|
|
Agenda
|
Date and Time
Wednesday, March 27, 2019
6:00 PM - 8:00 PM
San Diego Convention Center
Room: 15AB
San Diego, CA
|
|
6:00 PM
|
Pre-Activity Learning Assessment and Opening Comments/Overview
Jeffrey Dunn, PharmD, MBA
|
|
6:05 PM
|
Assessing the Clinical Benefits and Appropriate Use of Immuno-Oncology Agents
Joan H. Schiller, MD
|
|
6:45 PM
|
Medical and Pharmacy Benefit Design Strategies for Immuno-Oncology Agents
Jeffrey Dunn, PharmD, MBA
|
|
7:15 PM
|
Care Coordination Strategies to Enhance Patient Outcomes with Immuno-Oncology Agents
John Fox, MD, MHA
|
|
7:40 PM
|
Audience Q&A Session
|
|
7:55 PM
|
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
|
|
8:00 PM
|
Adjournment
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-19-475-L01-P
Type of Activity: Application
|
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Americans with Disabilities Act
♿ Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.
Fee Information
No additional fee is required to attend this CME/CPE activity.
Please note: No additional fee is required to attend this CME/CPE activity; however, registration to the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019 is required.
Pre-registration will close at 12:00 pm on March 26, 2019.
Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
|
|
.jpg)